Proposed 1 st IS for Hepatitis E Virus RNA WHO/BS/
|
|
- Erick Stevenson
- 5 years ago
- Views:
Transcription
1 Proposed 1 st IS for Hepatitis E Virus RNA WHO/BS/ S. Baylis, Division of Virology, Paul-Ehrlich-Institut, Langen, Germany SoGAT XXII 14 th -15 th April 2011, Rome, Italy
2 Presented at: 3 rd WHO CC Meeting 7 th -8 th March 2011, NIBSC, UK
3 HEV is a major cause of acute hepatitis Major public health concern in endemic areas (vaccine efforts) Emerging (more recognised) infection in industrialised countries High mortality in certain patients Individuals with liver disease Pregnant women Hepatitis E Virus (HEV) Immunosuppressed chronic infections increasingly recognised, load testing important in evaluation of antiviral therapy regimes Zoonotic virus, certain genotypes - swine and other animals Testing important in patients where other causes of hepatitis have been excluded (global issue) HEV can be transmitted by transfusion, present in donors
4 Background Project proposed at the 2 nd WHO CC Meeting in Langen, Feb Presented at SoGAT XX in Brussels, May 2009 and flagged for development in SoGAT survey Project proposal endorsed by ECBS in Oct (WHO/BS/ ) Anticipated users Clinical laboratories (hepatitis reference centres) Blood banks/plasma centres some are screening Research laboratories and vaccine developers IVD manufacturers (single commercial assay)
5 1 st Collaborative Study Aim & Approach To investigate HEV NAT assay performance for the first time using blinded panel of samples To determine an appropriate strain to develop into a candidate IS The panel comprised 22 HEV positive samples (10-fold serial dilutions) and 2 negative plasma controls genotypes 3a, 3b, 3f, 4c (zoonotic genotypes) Positive plasma samples obtained from blood donors Japan and Germany
6 HEV Strains Investigated in 1 st Study Genotype Virus strain HEV RNA (copies/ml) Anti-HEV IgM/IgG ALT (IU/L) 3a HRC-HE x /- 36 3b JRC-HE3 2.5 x / f RKI 1.3 x /- Negative 4c HRC-HE x /- 505
7 1 st Collaborative Study Labs & Methods 20 participating laboratories, from 10 countries Participants have expertise in molecular analysis of HEV Requested to use regular assays for HEV RNA and report results as either positive or negative i.e. HEV RNA detected or not detected Data was returned from 24 different assays 10 labs returned quantitative data (optional) All assays, except one, were developed in-house using conventional or real-time RT-PCR methodologies
8 Example - Qualitative Analysis of HRC-HE104 (Genotype 3a) Nominal concentration (log 10 copies/ml) Lab no / a b / / / a b + + +/ a b a b /- - Total number of tests Percentage positive /88 75/67 38/25 13/8
9 Quantitative Analysis of HEV Panel Virus strain HRC-HE104 Nominal concentration log 10 copies/ml N Geometric mean Median Min. Max JRC-HE RKI HRC-HE
10 Analysis of Titres and C T Values - HRC-HE104
11 1 st Collaborative Study Conclusions Qualitative data ~100- to 1000-fold difference in sensitivity - majority of assays, independent of strain real-time RT-PCR methods were most sensitive ORF1 assays were least sensitive Quantitative data at least two thirds of the data sets fell within ± 0.5 log 10 copies/ml of the geometric mean value for the different HEV strains All negative plasma samples were correctly reported (single equivocal result for one replicate sample) One false positive result, genotyping by the lab in question detected gt 1 (not included in the panel)
12 1 st Collaborative Study Outcome Project progress report submitted to WHO in Q2, 2010; recommendation to take forward the high titre genotype 3 samples as candidate standards well detected in study represent globally distributed genotype The following strains were lyophilised in September 2010 HRC-HE104 (genotype 3a) JRC-HE3 (genotype 3b) Diluted in citrated plasma used in 1 st study which tested negative for HIV-1/2 RNA, HCV RNA, HBV DNA Roche TaqScreen MPX HEV RNA and anti-hev (IgM and IgG)
13 Candidate WHO Standard Genotype 3a strain - candidate WHO standard Coefficient of variation of fill volume 1.1% Residual moisture 0.73% 4251 vials filled Titre of HEV RNA ~5-5.5 log 10 copies/ml (no loss post-lyophilisation) Full length sequence nearing completion Candidate WHO standard being evaluated together with the genotype 3b strain in a new collaborative study
14 2 nd Collaborative Study The study is being run in conjunction with the Japanese National Institute for Infectious Diseases (NIID) developing national standard (genotype 3b) 24 participating laboratories, from 10 countries Each laboratory was sent 4 vials of each candidate Sample 1 + Sample 2 - HRC-HE104 (genotype 3a) Sample 3 + Sample 4 - JRC-HE3 (genotype 3b) Samples shipped at ambient temperature Data returned by 23 laboratories, all in house assays 21 qualitative data sets, 14 quantitative data sets
15 Log 10 copies/ml 2 nd Collaborative Study contd. Data analysis in progress Stability studies are on-going Submission to ECBS June 2011 Candidate Mean log 10 copies/ml SD 95% CI %GCV WHO NIID Participant
16 Acknowledgements Keiji Matsubayashi, Japanese Red Cross Hokkaido Blood Center Collaborative study participants
17 NIID Candidate WHO Candidate
Hepa%%s E Virus Is it a Concern?
IPFA/PEI 17 th Workshop on Surveillance and Screening of Blood Borne Pathogens 26-27 May 2010, The Regent Esplanade Zagreb Hotel, Zagreb, Croa%a Hepa%%s E Virus Is it a Concern? Keiji Matsubayashi Hokkaido
More informationPROPOSAL FOR THE DEVELOPMENT OF AN INTERNATIONAL REFERENCE PREPARATION FOR HEPATITIS D VIRUS RNA
PROPOSAL FOR THE DEVELOPMENT OF AN INTERNATIONAL REFERENCE PREPARATION FOR HEPATITIS D VIRUS RNA SoGAT Clinical Diagnostics II 30 September / 1 October 2009, Istanbul Michael Chudy Julia Kreß C. Micha
More informationExperience with Standardisation of Blood Virology NAT. Clare Morris Division of Retrovirology National Institute for Biological Standards and Control
Experience with Standardisation of Blood Virology NAT Clare Morris Division of Retrovirology National Institute for Biological Standards and Control Background of Blood Virology Standardisation In the
More informationUpdate from ISS on following EQA studies: ISS EQA Tri-NAT (HCV, HIV and HBV) 2012 ISS EQA NAT HBV 2012 ISS EQA NAT WNV 2012
Update from ISS on following EQA studies: ISS EQA Tri-NAT (HCV, HIV and HBV) 2012 ISS EQA NAT HBV 2012 ISS EQA NAT WNV 2012 SOGAT XXIV Ljubljana, 8-9 May 2013 2012 ISS EQAs for NAT ISS EQA Tri-NAT (HCV,
More informationStandardization: Calibration of. International Standards, reference preparations and working standards. Micha Nübling, PEI
Standardization: Calibration of International Standards, reference preparations and working standards Micha Nübling, PEI Paul-Ehrlich-Institut Governmental Authority for biological medicinal products Blood
More informationWHO Parvovirus B19 Genotype Panel
WHO Parvovirus B19 Genotype Panel Mei-ying W Yu, PhD SoGAT XXII Rome, 14-15 April 2011 1 st WHO International Reference Panel for Parvovirus B19 Genotypes In Oct 2009, a plasma-derived parvovirus B19 (B19V)
More informationSally A. Baylis,* Kay-Martin Hanschmann, Johannes Blümel, and C. Micha Nübling on behalf of the HEV Collaborative Study Group
JOURNAL OF CLINICAL MICROBIOLOGY, Apr. 2011, p. 1234 1239 Vol. 49, No. 4 0095-1137/11/$12.00 doi:10.1128/jcm.02578-10 Copyright 2011, American Society for Microbiology. All Rights Reserved. Standardization
More informationHepatitis E Virus. Sally A. Baylis, Division of Virology, Paul-Ehrlich-Institut, Langen, Germany
Hepatitis E Virus www.pei.de Sally A. Baylis, Division of Virology, Paul-Ehrlich-Institut, Langen, Germany 20 th IPFA/PEI Workshop Lanzarote, 13 th -17 th May 2013 Background to HEV Blood and plasma issues
More informationCalibration and stability of WHO and secondary viral standards
Calibration and stability of WHO and secondary viral standards Nico Lelie, Harry van Drimmelen and the International NAT Study Group Facilities DDL Diagnostic Laboratories Outline Calibration of WHO and
More informationDEVELOPMENT OF AN INTERNATIONAL REFERENCE PREPARATION FOR HEPATITIS D VIRUS RNA - UPDATE
DEVELOPMENT OF AN INTERNATIONAL REFERENCE PREPARATION FOR HEPATITIS D VIRUS RNA - UPDATE SoGAT Clinical Diagnostics III 12-13 January 2011, London Michael Chudy Julia Kreß Micha Nübling Paul-Ehrlich-Institut
More informationExternal Quality Assessment Programmes (EQAPs) for blood-borne viruses: the Italian experience
External Quality Assessment Programmes (EQAPs) for blood-borne viruses: the Italian experience Giulio Pisani Biologicals Unit CRIVIB, ISS, Rome SOGAT XXII 14 th 15 th April 2011 - Istituto Superiore di
More informationHEV Assay Development Update
HEV Assay Development Update Jeffrey M. Linnen, Ph.D. Senior Director, Research & Development Hologic Gen-Probe, San Diego, California USA IPFA/PEI 20th International Workshop on Surveillance and Screening
More informationUpdate on the. Clinical Diagnostics. and. Blood Testing. Meetings of SoGAT. Micha Nübling, PEI.
Update on the www.pei.de Clinical Diagnostics and Blood Testing Meetings of SoGAT Micha Nübling, PEI SoGAT Since 1995: 22 SoGAT meetings (organized by NIBSC) 1-2 meetings/year (connected with IPFA workshop)
More informationInstructions for Use (Version 3-14 th May 2003) Changes from previous version are shown in Red, deletions are shown as ^
Page 1 of 5 Page 1 of 5, 97/656 WHO 1 st International Standard for HIV-1 RNA for Nucleic Acid-Based Techniques (NAT) NIBSC code: 97/656 Instructions for Use (Version 3-14 th May 2003) Changes from previous
More informationStability of native, lyophilized and inactivated standards
Stability of native, lyophilized and inactivated standards Harry van Drimmelen Bio Quality Control, Heiloo, Netherlands Satellite Meeting before IPFA-PEI 25 th Workshop Twenty-five Years Standardization
More informationJohn Saldanha Regulatory Requirements: Precision and Accuracy of Quantitative NAT Tests XXII SoGAT Meeting, April, 2011
John Saldanha Regulatory Requirements: Precision and Accuracy of Quantitative NAT Tests XXII SoGAT Meeting, 14 15 April, 2011 Istituto Superiore di Sanita (ISS), Rome, Italy 2 June 2011 page 1 2011 Roche
More informationHepatitis E Vaccine Clinical Experience. Mrigendra P. Shrestha
Hepatitis E Vaccine Clinical Experience Mrigendra P. Shrestha 1 Hepatitis E in Nepal 2 Hepatitis E in Nepal Most common type of acute viral hepatitis Occurs in annual rainy season outbreaks Responsible
More information1 st International Reference Panel for HIV-1 RNA Genotypes NIBSC code: 01/466
1 st International Reference Panel for HIV-1 RNA Genotypes NIBSC code: 01/466 Instructions for Use (8 th September 2004, Version 3) Changes from previous version are highlighted in red, deletions are shown
More informationThe Alphabet Soup of Viral Hepatitis Testing
The Alphabet Soup of Viral Hepatitis Testing August 18, 2011 Patricia Slev, PhD, DABCC Medical Director, Serologic Hepatitis and Retrovirus Laboratory, ARUP Laboratories Assistant Professor of Pathology,
More informationNew proposals for WHO International Standards for Human Herpesvirus 6 and Adenovirus
New proposals for WHO International Standards for Human Herpesvirus 6 and Adenovirus Jacqueline Fryer Division of Virology, NIBSC National Institute for Biological Standards and Control Assuring the quality
More informationViral Hepatitis Diagnosis and Management
Viral Hepatitis Diagnosis and Management CLINICAL BACKGROUND Viral hepatitis is a relatively common disease (25 per 100,000 individuals in the United States) caused by a diverse group of hepatotropic agents
More informationTest Name Results Units Bio. Ref. Interval
LL - LL-ROHINI (NATIONAL REFERENCE 135091650 Age 49 Years Gender Male 29/8/2017 120000AM 29/8/2017 100248AM 29/8/2017 105306AM Ref By Final HEATITIS, VIRAL, COMREHENSIVE ANEL HEATITIS A ANTIBODY (ANTI
More informationDiagnostic Methods of HBV and HDV infections
Diagnostic Methods of HBV and HDV infections Zohreh Sharifi,ph.D Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine Hepatitis B-laboratory diagnosis Detection
More informationE E Hepatitis E SARS 29, Lancet. E A B Enterically-Transmitted Non-A, Hepatitis E. Virus HEV nm. 1.35g/cm s ALT AST HEV HEV
7850 2004 Hepatitis E Tian-Cheng LI Naokazu TAKEDA Tatsuo MIYAMURA SARS 8 Lancet E E E Hepatitis E VirusHEV E E HEV HEV E 1955 29,000 E E A A B Enterically-Transmitted Non-A, Non-B Hepatitis 1983 Balayan
More informationEvaluation of run controls for cobas 6800 MPX and HEV assay
Evaluation of run controls for cobas 6800 MPX and HEV assay Marco Koppelman Head of Nucleic Acid testing (NAT) laboratory, National Screening laboratory of Sanquin (NSS) in the Netherlands Satellite Meeting
More informationGlecaprevir-Pibrentasvir in HCV GT 1 or 4 & Prior DAA Treatment MAGELLAN-1 (Part 2)
Phase 3 Treatment-Experienced in HCV GT 1 or 4 & Prior DAA Treatment MAGELLAN-1 (Part 2) in HCV GT 1 or 4 & Prior DAA Treatment MAGELLAN-1 (Part 2): Study Features MAGELLAN-1 (Part 2) Trial Design: Randomized,
More informationEXPERT COMMITTEE ON BIOLOGICAL STANDARDIZATION Geneva, 12 to 16 October 2015
EXPERT COMMITTEE ON BIOLOGICAL STANDARDIZATION Geneva, 12 to 16 October 2015 WHO/BS/2015.2262 ENGLISH ONLY Collaborative Study to Evaluate the Proposed 5 th WHO International Standard for Hepatitis C Virus
More informationEC CERTIFICATE. National Institute for Biological Standards and Control (NIBSC) Blanche Lane South Mimms Potters Bar Hertfordshire EN6 3QG UK
National Institute for Biological Standards and Control (NIBSC) EC Certificate - Full Quality Assurance System Approval Certificate Annex IV (excluding sections 4 and 6) of Council Directive 98/79/EC on
More informationHEV Update Blood Components. Dragoslav Domanović, European Centre for Disease Prevention and Control (Sweden)
HEV Update Blood Components Dragoslav Domanović, European Centre for Disease Prevention and Control (Sweden) Outline ECDC activities started in 2015 to understand the epidemiology and burden of HEV infection
More informationQuantification of HBV, HCV genotype and HIV subtype panels
Quantification of HBV, HCV genotype and HIV subtype panels Harry van Drimmelen 1,2, Wim Quint 2, Nico Lelie 3 and the international NAT study group 1. Biologicals Quality Control, 2. DDL Diagnostic Laboratory,
More informationTest Name Results Units Bio. Ref. Interval
LL - LL-ROHINI (NATIONAL REFERENCE 135091608 Age 26 Years Gender Female 30/8/2017 92900AM 30/8/2017 94717AM 31/8/2017 90216AM Ref By Final HEATITIS ACUTE VIRUS CONFIRMATION HEATITIS A ANTIBODY (ANTI HAV),
More informationNAT Screening of Blood Donations in NBC, TRCS
IPFA/PEI, Italy NAT Screening of Blood Donations in NBC, TRCS 2000-2001 Clinical evaluation using COBAS AmpliiScreen HIV & HCV assays, (MP24) window period rate - 1 : 108,768 for HIV-1 and HCV 2002 Routine
More informationDonor Screening in The Region. Vincini GA NRL, Melbourne, Australia
Donor Screening in The Region Vincini GA NRL, Melbourne, Australia NRL Established in 1985 Not-for-profit organisation that exists to support laboratories that perform testing for the diagnosis and management
More informationCALIBRATION OF ANALYTICAL STANDARDS FOR HBV-DNA, HCV-RNA AND HIV-1 RNA IN GENOME COPIES BY A REFERENCE METHOD
CALIBRATION OF ANALYTICAL STANDARDS FOR HBV-DNA, HCV-RNA AND HIV-1 RNA IN GENOME COPIES BY A REFERENCE METHOD AAJ van Drimmelen, E.R. Bax and W.G.V. Quint, BioQControl (BQC), Delft Diagnostic Laboratories
More informationThe ABC s (and D & E s) of the Viral Hepatitides Part 2 DIAGNOSTIC TESTS 3/7/2013
The ABC s (and D & E s) of the Viral Hepatitides Part 2 Thomas Novicki PhD DABMM Clinical Microbiologist Division of Laboratory Medicine novicki.thomas@marshfieldclinic.org Objectives 2 1. Explain the
More informationDiagnostic Methods of HBV infection. Zohreh Sharifi,ph.D of Virology Research center, Iranian Blood Transfusion Organization (IBTO)
Diagnostic Methods of HBV infection Zohreh Sharifi,ph.D of Virology Research center, Iranian Blood Transfusion Organization (IBTO) Hepatitis B-laboratory diagnosis Detection of HBV infection involves
More informationNon-competitive Internal Control Concept for PCR-based Qualitative Assays
Christian O. Simon Roche Molecular Diagnostics Rotkreuz, CH Non-competitive Internal Control Concept for PCR-based Qualitative Assays 23 rd SoGAT Meeting, 16 th 17 th April, 2012, Vilnius, Lithuania Design
More informationEXPERT COMMITTEE ON BIOLOGICAL STANDARDIZATION Geneva, 17 to 21 October 2011
ENGLISH ONLY EXPERT COMMITTEE ON BIOLOGICAL STANDARDIZATION Geneva, 17 to 21 October 2011 Collaborative Study to Evaluate the Proposed 3 rd WHO International Standard for Hepatitis B Virus (HBV) for Nucleic
More informationOfficial Journal of the European Communities COMMISSION
16.5.2002 EN Official Journal of the European Communities L 131/17 COMMISSION COMMISSION DECISION of 7 May 2002 on common technical specifications for in vitro-diagnostic medical devices (notified under
More informationEXPERT COMMITTEE ON BIOLOGICAL STANDARDIZATION Geneva, 17 to 20 October 2017
WHO/BS/2017.2314 ENGLISH ONLY EXPERT COMMITTEE ON BIOLOGICAL STANDARDIZATION Geneva, 17 to 20 October 2017 International Collaborative Study to Establish the 4 th WHO International Standard for HIV-1 NAT
More informationKhalid Alquthami (Correspondence) Regional Lab, Makkah. Saudi Arabia
1 Regional Lab, Makkah. Saudi Arabia stract: Clinical specificity and genotype/subtype detection of viruses using the Cobas TaqScreen MPX system V 2.0, which is a nucleic acid test (NAT) that uses multiples
More informationVARIATION IN MEASUREMENT OF HIV RNA VIRAL LOAD
VARIATION IN MEASUREMENT OF HIV RNA VIRAL LOAD SOURCES OF VARIATION (RANDOM VS SYSTEMATIC) MAGNITUDE OF EACH SOURCE CONSEQUENCES FOR CONFIDENCE LIMITS AROUND MEASUREMENTS AND CHANGES DATA FROM ROCHE HIV
More informationBringing quantitative HBsAg to the US provider, drug development and patient network
Bringing quantitative HBsAg to the US provider, drug development and patient network Presenter Robert G Gish MD Adjunct Professor, Stanford University Medical Director HBV Foundation HBV Forum 3 October
More informationThe ABCs of Viral Hepatitis Diagnosis. Ila Singh, M.D., Ph.D. P & S Viral Hepatitis. Hepatitis A, B, C, D, E and G viruses
The ABCs of Viral Hepatitis Diagnosis Ila Singh, M.D., Ph.D. P & S 14-453 is132@columbia.edu Viral Hepatitis Hepatotropic viruses Hepatitis A, B, C, D, E and G viruses Generalized infection plus infection
More informationImpact of Testing Strategies to Reduce Transmission Risk for HBV. Ravi Reddy, M Vermeulen South African National Blood Service (SANBS) 29 July 2013
Impact of Testing Strategies to Reduce Transmission Risk for HBV Ravi Reddy, M Vermeulen South African National Blood Service (SANBS) 29 July 2013 Overview of SANBS SANBS is a private not for profit company
More informationInstruction to implement measures for risk minimisation in using HIV-1 NAT test systems
Paul-Ehrlich-Institut P.O. Box 63207 Langen, Germany To: The marketing authorisation holders of cellular blood products and fresh frozen plasma and the holders of authorisations for stem cell preparations
More informationRama Nada. - Malik
- 2 - Rama Nada - - Malik 1 P a g e We talked about HAV in the previous lecture, now we ll continue the remaining types.. Hepatitis E It s similar to virus that infect swine, so its most likely infect
More informationIntroduction: Table/Figure Descriptions:
Introduction: We have completed the analysis of your HIV RNA Validation Study. The validation plan was designed to verify the installation of an unmodified FDA-approved HIV RNA assay into your laboratory.
More informationTest Name Results Units Bio. Ref. Interval
LL - LL-ROHINI (NATIONAL REFERENCE 135091606 Age 24 Years Gender Male 30/8/2017 92800AM 30/8/2017 94631AM 31/8/2017 90306AM Ref By Final HEATITIS A & B VIRUS EVALUATION HEATITIS A ANTIBODY (ANTI HAV),
More informationEPIDEMIOLOGY, CLINICAL FEATURES AND OUTCOME OF ACUTE HEPATITIS C IN HIV-POSITIVE PATIENTS: PRESENTATION OF OUR EXPERIENCE
EPIDEMIOLOGY, CLINICAL FEATURES AND OUTCOME OF ACUTE HEPATITIS C IN HIV-POSITIVE PATIENTS: PRESENTATION OF OUR EXPERIENCE E. Angeli, A. Mainini, C. Atzori, G. Gubertini and G. Rizzardini II Dept. Infectious
More informationAccuVert HBV Seroconversion Panel PHM941(M) ( )
PACKAGE INSERT PHM941(M) (0605-0061) INTENDED USE PHM941(M) (0605-0061) is a group of serial bleeds from an individual plasma donor during HBV seroconversion. This panel is intended for use by diagnostics
More informationFifteen years of molecular EQA: progress and challenges
Fifteen years of molecular EQA: progress and challenges Anton M van Loon 1, Stuart West 2 and Paul Wallace 2 1 Department of Virology, UMC Utrecht, The Netherlands 2 QCMD, Glasgow, Scotland Key Issues
More informationNRL EQAS for NAT: Assessing the variability and performance of molecular assays for clinical pathogens
NRL EQAS for NAT: Assessing the variability and performance of molecular assays for clinical pathogens Vincini GA*, Cabuang LM, Land S, Best SJ NRL London, 12 January 2011 NRL EQAS for NAT HCV Genotyping
More informationHIV Basics: Clinical Tests and Guidelines
HIV Basics: Clinical Tests and Guidelines ACTHIV 2010 Zelalem Temesgen MD Mayo Clinic Topics Baseline laboratory evaluation Laboratory monitoring through the continuum of care Patients not on antiretroviral
More informationLearning Objectives: Hepatitis Update. Primary Causes of Chronic Liver Disease in the U.S. Hepatitis Definition. Hepatitis Viruses.
Learning Objectives: Hepatitis Update ASCLS-Michigan March 31, 2016 Dr. Kathleen Hoag Upon attendance of this seminar and review of material provided, the attendees will be able to: 1. List hepatitis viruses
More informationViral hepatitis. Supervised by: Dr.Gaith. presented by: Shaima a & Anas & Ala a
Viral hepatitis Supervised by: Dr.Gaith presented by: Shaima a & Anas & Ala a Etiology Common: Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Less common: Cytomegalovirus EBV Rare: Herpes
More informationEnd Stage Liver Disease & Disease Specific Indications for Liver Transplant. Susan Kang, RN, MSN, ANP-BC
End Stage Liver Disease & Disease Specific Indications for Liver Transplant Susan Kang, RN, MSN, ANP-BC Introduction (https://www.srtr.org) What does the liver do? STORAGE METABOLIC DETOXIFICATION SYNTHETIC
More informationEnd Stage Liver Disease & Disease Specific Indications for Liver Transplant Susan Kang, RN, MSN, ANP BC
End Stage Liver Disease & Disease Specific Indications for Liver Transplant Susan Kang, RN, MSN, ANP BC Introduction (https://www.srtr.org) 1 What does the liver do? STORAGE METABOLIC DETOXIFICATION SYNTHETIC
More informationIs it the time to start blood screening for Hepatitis-E?
Is it the time to start blood screening for Hepatitis-E? Dr. Somnath Mukherjee MD, MAMS Assistant Professor All India Institute of Medical Sciences Bhubaneswar During last 25 years the safety of blood
More informationUses and Misuses of Viral Hepatitis Testing. Origins of Liver Science
Uses and Misuses of Viral Hepatitis Testing Richard S Lang, MD, MPH, FACP Chairman, Preventive Medicine Vice-Chair, Wellness Institute Raul J Seballos, MD, FACP Vice-Chair, Preventive Medicine Wellness
More informationto be notified: all parties involved in the graduated plan procedure. Annexes
Paul-Ehrlich-Institut Postfach 63207 Langen, Germany To all marketing authorisation holders of cellular blood preparations and therapeutic single plasmas as well as authorisation holders of stem cells
More informationCMV Diagnostic Strategies: Current and Future
CMV Diagnostic Strategies: Current and Future Tony Mazzulli, MD, FRCPC, FACP Microbiologist-in-Chief Mount Sinai Hospital & University Health Network, Toronto Faculty/Presenter Disclosure Relationships
More informationDetection of IgA-class anti-hev antibody
Detection of IgA-class anti-hev antibody Hiroaki OKAMOTO E IgA-HE IgA HEV E HEV E E E 10 E 1997 E E 1, 2 2001 E 3 HEV 4 1979 HEV 5 A B C A B C E 6, 7 E HEV E 8 11 2003 8 19 http:www.mhlw. go.jphoudou200308h0819-2.html
More informationLaboratory Diagnosis of Viral Infections. G. Jamjoom 2005
Laboratory Diagnosis of Viral Infections G. Jamjoom 2005 Five Main Techniques: Virus Culture and Isolation Serology Rapid Detection of Viral Antigens Detection of Viral Nucleic Acid Electron Microscopy
More informationNegative Hepatitis C Reporting and Linkage to Care Outreach
Negative Hepatitis C Reporting and Linkage to Care Outreach NASTAD 7 th National Hepatitis Technical Assistance Meeting November 28-30, 2017 Angelica Bocour, MPH Director of Viral Hepatitis Surveillance
More informationNational Screening laboratory Sanquin The use of NAT in blood donation screening in The Netherlands. TransMed conference Bhopal 18 November 2016
Dr. Anton van Weert National Screening laboratory Sanquin The use of NAT in blood donation screening in The Netherlands TransMed conference Bhopal 18 Introduction Thank you! Anton van Weert, PhD, MBA Manager
More informationHuman diagnostics. Better be Sure: Quantify HDV & HBV viral load. RoboGene product family
Human diagnostics Better be Sure: Quantify HDV & HBV viral load. RoboGene product family 2 RoboGene Product Family Improved patient management: Standardized monitoring of HBV DNA and HDV RNA viral load.
More informationErratum to: A systematic review of the epidemiology of hepatitis E virus in Africa
Kim et al. BMC Infectious Diseases (2017) 17:187 DOI 10.1186/s12879-017-2274-3 ERRATUM Erratum to: A systematic review of the epidemiology of hepatitis E virus in Africa Open Access Jong-Hoon Kim 1*, Kenrad
More informationHBV-DNA reference panels
HBV-DNA reference panels The kit insert contains a detailed protocol and should be read carefully before testing the run control to ensure optimal performance Table of contents Overview HBV-DNA panels
More informationCustomer Service and Ordering Address Biologicals Quality Control B.V. Droogmakerij 31h 1851 LX Heiloo The Netherlands
PRODUCT CATALOGUE Customer Service and Ordering Address Biologicals Quality Control B.V. Droogmakerij 31h 1851 LX Heiloo The Netherlands Communication +31 72 202 07 30 +31 72 202 07 31 sales@bioqcontrol.com
More informationINTERNATIONAL WORKING GROUP ON THE STANDARDISATION OF GENOME AMPLIFICATION TECHNIQUES (SoGAT) FOR CLINICAL DIAGNOSTICS
INTERNATIONAL WORKING GROUP ON THE STANDARDISATION OF GENOME AMPLIFICATION TECHNIQUES (SoGAT) FOR CLINICAL DIAGNOSTICS SoGAT Clinical Diagnostics I, 24-25 June 2008 National Institute for Biological Standards
More informationHepatitis B Antiviral Drug Development Multi-Marker Screening Assay
Hepatitis B Antiviral Drug Development Multi-Marker Screening Assay Background ImQuest BioSciences has developed and qualified a single-plate method to expedite the screening of antiviral agents against
More informationTitle: Reactivation of a Hepatitis B without core antibody: a case report.
JCM Accepted Manuscript Posted Online 28 January 2015 J. Clin. Microbiol. doi:10.1128/jcm.03546-14 Copyright 2015, American Society for Microbiology. All Rights Reserved. 1 1 Title: Reactivation of a Hepatitis
More informationOpportunities Created by Diagnostic HCV and HIV Nucleic Acid Tests
Opportunities Created by Diagnostic HCV and HIV Nucleic Acid Tests Ann Winters, MD Medical Director, Viral Hepatitis Program, Bureau of Communicable Disease, New York City Department of Health and Mental
More informationNew recommendations for immunocompromised patients
New recommendations for immunocompromised patients Hepatitis E Virus (HEV): Transmission, incidence and presentation Emerging evidence regarding HEV transmission from blood components and dietary consumption
More informationEmerging TTIs How Singapore secure its blood supply
Emerging TTIs How Singapore secure its blood supply Ms Sally Lam Acting Division Director I Blood Supply Management I Blood Services Group I Health Sciences Outline Risk Mitigation Strategies to secure
More informationHepatitis Delta. Vicente Soriano Infectious Diseases Unit La Paz University Hospital & IdiPAZ Madrid, Spain
Hepatitis Delta Vicente Soriano Infectious Diseases Unit La Paz University Hospital & IdiPAZ Madrid, Spain Disclosures Member of speaker bureau and advisory board for: Roche, Boehringer, Gilead, Viiv,
More information-HCV genome is about 9400 nucleotides long, it is ssrna and positive sense -the 10 viral proteins are first made as a large polyprotein -individual
2013: HCV Genome -HCV genome is about 9400 nucleotides long, it is ssrna and positive sense -the 10 viral proteins are first made as a large polyprotein -individual proteins are released from polyprotein
More informationThe use of QCMD proficiency testing panels in clinical virology.
The use of QCMD proficiency testing panels in clinical virology. Prof.dr. Bert Niesters Department of Medical Microbiology Division of Clinical Virology UMC Groningen Disease Disease Management Viral Load
More informationTransmission of HCV in the United States (CDC estimate)
Transmission of HCV in the United States (CDC estimate) Past and Future US Incidence and Prevalence of HCV Infection Decline among IDUs Overall incidence Overall prevalence Infected 20+ years Armstrong
More informationFrequency of occult hepatitis B in HBsAg seronegative blood donors in a tertiary care hospital in kerala,south India.
Frequency of occult hepatitis B in HBsAg seronegative blood donors in a tertiary care hospital in kerala,south India. Cinzia Keechilot, Veena Shenoy 1,V Anil kumar 2,Lalita Biswas 3. MBBS student * Transfusion
More informationThe Technical Aspects of Pathogen Testing in Canada. Nancy Angus Canadian Blood Services Director, Testing
PERMISSON TO USE: Please note that, by making their presentations available on-line, primary authors have agreed to share their presentations. However, should you want to use some of the data or slides
More informationP0141 HBV 1000 copies/ml genotype reference panel
P0141 HBV 1000 copies/ml genotype reference panel P0141 The kit insert contains a detailed protocol and should be read carefully before testing the run control to ensure optimal performance Table of contents
More informationImpact of multi-dye multiplex technology on testing algorithm
Impact of multi-dye multiplex technology on testing algorithm Lydia Blanco. Mª Isabel Gonzalez-Fraile Centro de Hemoterapia y Hemodonación de Castilla y León, España TTI EPIDEMIOLOGICAL DATA IN SPAIN NAT
More informationCase Study. Dr Sarah Sasson Immunopathology Registrar. HIV, Immunology and Infectious Diseases Department and SydPath, St Vincent's Hospital.
Case Study Dr Sarah Sasson Immunopathology Registrar HIV, Immunology and Infectious Diseases Department and SydPath, St Vincent's Hospital Case 1: Case 1: 45F in Cameroon Cameroon HIV+ Presents with cutaneous
More informationThis document is meant purely as a documentation tool and the institutions do not assume any liability for its contents
2002D0364 EN 01.07.2012 002.001 1 This document is meant purely as a documentation tool and the institutions do not assume any liability for its contents B COMMISSION DECISION of 7 May 2002 on common technical
More informationHEPATITIS VIRUSES. Other causes (not exclusively hepatitis v.)also called sporadic hepatitis: HEPATITIS A(infectious hepatitis)
Dept.of Microbiology/Virology Assist.prof. Shatha F. Abdullah HEPATITIS VIRUSES Medically important hepatitis v. (liver)are: 1.HAV 2.HBV 3.HCV 4.HDV 5.HEV 6.HGV Other causes (not exclusively hepatitis
More informationEpidemiological profiles of viral hepatitis in Italy Effects of migration
Epidemiological profiles of viral hepatitis in Italy Effects of migration Hepatitis A and E T. Santantonio UOC di Malattie Infettive Università degli Studi di Foggia Azienda Ospedaliero-Universitaria Ospedali
More informationAssays to Address Emerging Threats to Blood Safety
Assays to Address Emerging Threats to Blood Safety Jeffrey M. Linnen, Ph.D. Director, Product Development Gen-Probe Incorporated San Diego, CA The IPFA/PEI 17th Workshop on Surveillance and Screening of
More informationNAT / BLOOD SCREENING - PRODUCT RANGE
NAT / BLOOD SCREENING - PRODUCT RANGE QC Sample Name Analytes Assay / Instrument Page QConnect TriScreen Roche cobas TaqScreen MPX Test, v 2.0 (s201) Roche cobas MPX Test (6800/8800) QConnect Grifols Ultrio
More informationHepatitis E and the English blood supply
Hepatitis E and the English blood supply Mhairi Webster Microbiology Senior Scientist National Transfusion Microbiology Reference Laboratory With thanks to Dr Alan Kitchen Hepatitis E virus Small, non-enveloped
More informationJune Pre-evaluation of the External Quality Assessment Schemes in Virus Diagnostics. Prof. Dr. Heinz Zeichhardt. Dr.
June 2018 Pre-evaluation of the External Quality Assessment Schemes in Virus Diagnostics Prof. Dr. Heinz Zeichhardt Dr. Martin Kammel Issued by: INSTAND Gesellschaft zur Förderung der Qualitätssicherung
More informationNew HIV Tests and Algorithm: A change we can believe in
New HIV Tests and Algorithm: A change we can believe in Esther Babady, PhD, D (ABMM) Memorial Sloan-Kettering Cancer Center New York, New York Learning Objectives After this presentation you should be
More informationCustomer Service and Ordering Biologicals Quality Control B.V. Droogmakerij 31h 1851 LX Heiloo The Netherlands
PRODUCT CATALOGUE Customer Service and Ordering Biologicals Quality Control B.V. Droogmakerij 31h 1851 LX Heiloo The Netherlands Communication +31 72 202 07 30 +31 72 202 07 31 info@bioqcontrol.com www.bioqcontrol.com
More informationWHO/BS/ ENGLISH ONLY
ENGLISH ONLY EXPERT COMMITTEE ON BIOLOGICAL STANDARDIZATION Report on the WHO collaborative study to establish the 1 st International Standard for anti-ev71 serum (Human) Gillian Cooper 1,4, Qunying Mao
More informationTransmission of HEV by plasmapheresis. Vincent Mallet, MD, PhD CHU Cochin, Université Paris Descartes, APHP, Inserm
Transmission of HEV by plasmapheresis Vincent Mallet, MD, PhD CHU Cochin, Université Paris Descartes, APHP, Inserm Transmission of HEV by secured plasma Transmission of HEV by plasma IA Transmission of
More informationHepatitis C Management and Treatment
Hepatitis C Management and Treatment Kaya Süer Near East University Faculty of Medicine Infectious Diseases and Clinical Microbiology 1 Discovery of Hepatitis C Key facts Hepatitis C: the virus can cause
More informationCommonly Asked Questions About Chronic Hepatitis C
Commonly Asked Questions About Chronic Hepatitis C From the American College of Gastroenterology 1. How common is the hepatitis C virus? The hepatitis C virus is the most common cause of chronic viral
More informationRoche Molecular Biochemicals Application Note No. HP 1/1999
Roche Molecular Biochemicals Application Note No. HP 1/1999 Nucleic Acid Purification High Pure Viral Nucleic Acid Kit High Pure 16 System Viral Nucleic Acid Kit Efficiency of Hepatitis C Virus sample
More information